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Case report
Bronchiolitis obliterans organizing pneumonia and ulcerative colitis
after allogeneic bone marrow transplantation
FA Baron1, J-P Hermanne1, A Dowlati1, T Weber2, A Thiry3, M-F Fassotte1, G Fillet1
and Y Beguin1
Department of Medicine, Divisions of 1Hematology and 2Pneumology, and 3Department of Pathology, University of Lie`ge, Belgium
Summary:
A 37-year-old man with acute myeloblastic leukemia in
first remission developed ulcerative colitis and
bronchiolitis obliterans organizing pneumonia (BOOP)
7 months after bone marrow transplantation (BMT)
from an HLA-matched brother who suffered from sev-
ere Crohn’s disease. BOOP occurred 20 days after idio-
pathic interstitial pneumonia, in the context of severe
ulcerative colitis. Lung and colon biopsies showed no
signs of CMV infection or GVHD. The patient was
treated with oral methylprednisolone 1 mg/kg/day and
his clinical status and chest X-ray improved slowly.
Remarkably, the symptoms of colitis also resolved with
prednisone therapy and he is now symptom-free. We
hypothesize that ulcerative colitis may have been trans-
mitted from donor to recipient (adoptive autoimmunity)
and that it was complicated by BOOP. However, other
factors such as CMV may have contributed to the
occurrence of BOOP.
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Bronchiolitis obliterans organizing pneumonia (BOOP) is
a rare cause of diffuse infiltrative lung disease. It may be
idiopathic or occur in association with infections, drugs or
miscellaneous neoplastic or inflammatory diseases. The
first case of BOOP following bone marrow transplantation
(BMT) was described in 1990.1 Since then, six additional
cases of BMT-associated BOOP have been reported (Table
1), including two successive episodes in a single patient
undergoing two BMT procedures.2–4 BOOP has also been
described in several patients with inflammatory bowel dis-
ease.5 We report a new case of BMT-associated BOOP
which developed in the recipient of a marrow transplant
from a donor who suffered from Crohn’s disease. As the
patient simultaneously developed ulcerative colitis and
BOOP about 6 months after BMT, this observation could
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constitute a case of adoptive autoimmunity in which trans-
mission from donor to recipient of inflammatory bowel
disease could have contributed to the pathogenesis of BMT-
associated BOOP.
Case report
The patient, a 37-year-old man with acute myeloblastic
leukemia in first remission, received a genotypically HLA-
identical BMT from his brother in March 1995. The donor
was negative for cytomegalovirus (CMV) on serology but
had suffered from severe Crohn’s disease for the past 15
years, which was treated with sulfasalazine and azathio-
prine. The latter was stopped 3 weeks before the transplant.
The recipient was positive for CMV. Pre-transplant pul-
monary function tests were normal. Conditioning consisted
of cytarabine 12 g/m2, cyclophosphamide 120 mg/kg and
single dose total body irradiation (TBI) 8 Gy. Graft-versus-
host disease (GVHD) prophylaxis was carried out with
short methotrexate and cyclosporine (CsA).
The initial post-transplant course was complicated by
grade 1 acute skin GVHD that resolved after increasing the
dose of cyclosporine. He never developed any sign of clini-
cal or subclinical chronic GVHD. On day 162, he experi-
enced generalized seizures (attributed to severe hyperten-
sion and CsA) and was started on phenobarbital and
clonazepam while CsA was stopped. Cerebral spinal fluid
examination and cerebral CT scan and NMR were all nor-
mal. Shortly afterwards, he developed diffuse abdominal
pain with bloody diarrhea. Rectosigmoidoscopic examin-
ation performed on day 167 showed severe ulcerative and
hemorrhagic colitis involving the rectum and whole sig-
moid colon. Biopsies (Figure 1) showed ulcerative colitis
with no sign of CMV infection or GVHD. Immunohistol-
ogy demonstrated a mixture of T and B cells with a pre-
dominance of B cells. Stool cultures and search for Clostri-
dium difficile toxin remained negative. Twenty days later,
he developed fever and a rapidly progressive interstitial
pneumopathy that required ventilation. Bronchoalveolar
lavage (BAL) was noncontributive and in situ hybridiz-
ation, as well as blood and urine cultures, failed to detect
CMV, although CMV reactivation had been detected by
serology in the preceding 2 months. Treatment with high-
dose immunoglobulins, ganciclovir, imipenem, doxycycline
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Table 1 Reported cases of BMT-associated BOOP
Case number 1 2a 3a 4 5 6 7 8
Author Chien1 Thirman2 Thirman2 Mathew3 Mathew3 Mathew3 Przepiorka4 Baron
(this report)
Age 31 37 42 15 10 12 23 37
Sex M M M M M M F M
Disease AML CML CML ALL AML ALL ALL AML
Graft
Type Sibling Sibling Sibling Unrelated Unrelated Sibling Sibling Sibling
HLA mismatches 0 0 0 0 0 2 1 0
Conditioning NR Cy + TBI Bu Cy AraC + Cy AraC + Cy AraC + Cy Cy + Thiotepa AraC + Cy
+ AraC + TBI + TBI + TBI + TBI + TBI
GVHD prophylaxis NR MTX + ATG CsA PDN PDN PDN CsA + PDN CsA + MTX
+ PDN + aCD5
aGVHD
Grade NR 1 3 0 0 0 2 1
Resolved Yes Yes Yes Yes Yes
cGVHD
Organ NR Liver Skin None Skin None None None
Day 210 190 155
Treatment NR CsA + PDN PDN
Outcome resolved improved resolved





+ IVIg + IVIg + AB
Resolved Yes Yes
GI involvement Yes No Yes NR NR NR NR Yes
Symptoms diarrhea bleeding diarrhea
+ bleeding
Etiology aGVHD CMV ulcerative
colitis
BOOP
Day 180 240 128 94 89 110 140 205
BAL lymphocytosis NR sterile parinfluenza NR parinfluenza sterile sterile
Biopsy BOOP BOOP Non- BOOP BOOP BOOP BOOP BOOP
diagnostic
Treatment Steroids Steroids Steroids Sterois Steroids Steroids Steroids Steroids
+ IVIg + IVIg
Outcome Resolved Resolved Resolved Resolved Resolved Death from Death from Resolved
MOF RF
aSame patient
NR = not reported; MOF = multiple organ failure; RF = respiratory failure; IP = interstitial pneumonia; AML = acute myelogenous leukemia; ALL =
acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; Cy = cyclophosphamide; AraC = arabinoside cytosine; Bu = busulfan; TBI =
total body irradiation; aGVHD = acute GVHD; cGVHD = chronic GVHD; BAL = bronchoalveolar lavage; GI = gastrointestinal; PDN = prednisone;
CsA = cyclosporine; MTX = methotrexate; ATG = antithymocyte globulin; aCD5 = anti-CD5 monoclonal antibody; IVIg = intravenous immunoglobulins;
AB = antibiotics.
and amphotericin B resulted in progressive improvement
and extubation 3 days later, followed by progressive nor-
malization of his chest X-ray film. However, he continued
to suffer from bloody diarrhea and a second rectosigmoido-
scopy confirmed the previous diagnosis of ulcerative colitis.
On day 205, a routine chest X-ray film showed interstitial
infiltration of the lower right lobe, which rapidly progressed
to diffuse acino-interstitial infiltrates despite treatment with
ganciclovir, erythromycin, amphotericin B and polyvalent
immunoglobulins. The patient had no fever, but a non-pro-
ductive cough, hypoxemia at rest and inspiratory crackles
on chest examination. Bronchoalveolar lavage was non-
contributory but open lung biopsy showed BOOP (Figure
2). In situ hybridization did not demonstrate the presence of
CMV. The patient was started on oral methylprednisolone 1
mg/kg/day and improved slowly. Methylprednisolone 40
mg daily was continued for 3 months and then tapered over
a few weeks. Since stopping steroids 18 months ago, he
has remained in good clinical condition without recurrence
of BOOP. Remarkably, the symptoms of colitis resolved
with the prednisone therapy and he his now symptom-free.
Discussion
We report a patient who simultaneously developed BOOP
and ulcerative colitis 6 months after allogeneic BMT.
Although its physiopathology remains unclear, BOOP has
been observed in the context of various autoimmune dis-
orders and in particular inflammatory bowel diseases.5 The
pathogenesis of ulcerative colitis remains unclear but auto-
immunity has been highlighted among genetic, allergic,
BOOP and ulcerative colitis after BMT
FA Baron et al
953
Figure 1 Colon biopsies showing diffuse superficial cell degeneration
with severe congestion of the lamina propria. Crypts showed derangement
of their normal architecture as well as goblet cell depletion and a diffuse
moderate inflammation of the lamina propria.
Figure 2 Open lung biopsy showing a regularly arranged inflammatory
exudate and plugs of connective tissue distributed within terminal bronchi
and bronchioles. Alveoli contained foamy macrophages and inflamma-
tory cells.
dietary, infectious and immunologic mechanisms, and
immunosuppressive agents such as prednisolone or cyclo-
sporine can improve it. In the context of BMT, these two
infrequent diseases may also have a toxic, infectious or
GVHD-related etiology.
BOOP has been associated with radiation therapy as well
as several drugs, including anti-inflammatory and immuno-
suppressive agents such as gold, methotrexate and sulfasal-
azine.5 In all cases of BMT-related BOOP, the preparative
regimen included cyclophosphamide and in seven of eight
cases total body irradiation (TBI) (Table 1). However, the
delay between conditioning and the onset of symptoms ren-
ders this explanation unlikely in our patient. Ulcerative col-
itis following BMT may also have a toxic origin but excep-
tionally so after day 100 post-BMT.6
The first reported case of BMT-related BOOP followed
CMV interstitial pneumonia.1 Moreover, ulcerative colitis
may also be due to viral (such as CMV or HSV) infections.
Our patient also developed BOOP after interstitial pneumo-
nitis in the context of serologic CMV reactivation. How-
ever, examination of bronchoalveolar lavage, lung and
colon biopsies, as well as blood and urine cultures failed
to detect CMV or other viral infections.
BOOP has also been associated with chronic GVHD in
three of the eight reported cases (Table 1).2 No case has
been described following autologous BMT and this may
indicate that host–recipient interactions play an important
role in BMT-related BOOP. Necrosis of the intestinal
mucosa is typical of acute GVHD, but is unusual after day
100 and is not part of the chronic GVHD syndrome charac-
terized by patchy fibrosis of the lamina propria and striking
fibrosis of the submucosa and serosa extending from the
stomach to the colon.6 Moreover, in our patient colon
biopsies showed no sign of acute or chronic GVHD.
After allogeneic BMT, there is gradual development of
donor-derived immunity, which generally recapitulates
immune ontogeny.7 Two distinct conditions may develop in
this setting, ie eradication of pre-existent immune-mediated
diseases and conversely, adoptive autoimmunity. Eradi-
cation of pre-existent immune-mediated disease has been
documented for several disorders, including rheumatoid
arthritis, systemic lupus, psoriasis, ulcerative colitis and
Crohn’s disease.8–10 Adoptive autoimmunity is well illus-
trated by the transfer of several autoimmune conditions
from donors to their recipients, including myasthenia
gravis, autoimmune thyroiditis and type 1 diabetes mel-
litus.7,9,10 It is caused by donor-derived pathogenic B, T or
stem cell clones after regulatory and suppressive mech-
anisms are canceled by the conditioning regimen and
immune dysregulation in the recipient. Genuine adoptive
autoimmunity must be distinguished from autoimmunity
occurring in the context of GVHD or in an apparently idio-
pathic fashion.9
To date, no case of transmission of inflammatory bowel
disease from a marrow donor to its recipient has been
reported. A case of typical ulcerative colitis following BMT
has been reported (results of initial biopsies were nonspe-
cific but a repeat biopsy showed typical ulcerative colitis
that responded well to topical and systemic corticosteroids)
but the donor had no gastrointestinal symptoms.11 How-
ever, this case may have originated from donor-derived cell
clones carrying the autoimmune potential. Our patient
developed a clinical picture of ulcerative colitis 6 months
after engraftment, soon after discontinuation of CsA.
Biopsies performed twice excluded diagnoses of virus- or
GVHD-induced colitis and all cultures remained negative.
Furthermore, the symptoms of colitis began after CsA was
discontinued and responded well to corticosteroids. Ulcer-
ative colitis and Crohn’s disease are thought to be related
diseases or even different manifestations of the same dis-
ease.12 This contention is well supported by epidemiologic
similarities and by the increased incidence of both diseases
in relatives of patients with Crohn’s disease. Therefore,
there is a possibility that the immune-mediated colitis seen
in our patient derived from the same lymphocyte clones
involved in the donor’s Crohn’s disease, constituting adop-
tive autoimmunity.
In conclusion, our patient developed two rare diseases,
ulcerative colitis and BOOP, 6 months after allogeneic
BMT, soon after cyclosporine was stopped. Both resolved
with prednisone therapy and 18 months later the patient is
symptom-free. These two disorders have been associated
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this represents the adoptive transfer of autoimmune ulcer-
ative colitis from donor to recipient complicated by BOOP.
However, other factors such as CMV or undetermined
infections may have contributed to the occurrence of
BOOP.
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